S16 Ep18: Integrating Novel Targets and Translational Insights Into SCLC Practice: With Anne Chiang, MD, PhD

Small cell lung cancer treatment has entered a new era since 2018, moving beyond traditional chemotherapy toward immunotherapy and targeted strategies that significantly improve median overall survival. Dr. Anne Chiang highlights the importance of understanding disease heterogeneity, exemplified by the Phase 2 S2409 PRISM trial, which uses molecular subtyping to guide maintenance therapy. Innovations like DLL3-targeted bispecific antibodies, such as tarlatamab, offer effective alternatives by bridging the immune system to cancer cells without relying on chemotherapy. Beyond clinical efficacy, treatment decisions require a holistic assessment of patient fitness, including geriatric metrics and social support, rather than relying solely on ECOG performance status. Ultimately, fostering transparent communication about prognosis and expectations remains vital for navigating the complexities of both curative-intent and palliative care, ensuring patients remain central to their evolving treatment plans.